🇺🇸 FDA

Intelligence · Patent portfolio

Takeda Patents

Full USPTO pharma patent portfolio for Takeda — grant dates, expiration, and drug cross-links.

Patents
1,436
Expiring ≤24m
81

Quick answer

Takeda has 1,436 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 81 expire within 24 months — use filters for patent-cliff planning.

Page 18 of 30

  1. US 8431116

    Norovirus vaccine formulations

    Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8431154

    Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient

    Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8426461

    Orally dispersible tablet

    Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8420816

    Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK

    Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8420694

    Pyrrolidin-2-one derivatives as androgen receptor modulator

    Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8415395

    Colchicine compositions and methods

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8415368

    Acid secretion inhibitor

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8415396

    Colchine compositions and methods

    Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8410087

    Indole compound

    Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8410089

    Fused heterocyclic ring compound

    Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8404643

    Metastin derivatives and use thereof

    Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8399449

    Fused heterocyclic derivative and use thereof

    Expires Mon Mar 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8394843

    Substituted isoindoles as glucokinase activators

    Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8383647

    Quinoline derivative

    Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8372872

    Methods for concomitant treatment of theophylline and febuxostat

    Expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8361968

    Metastin derivatives and use thereof

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8362211

    Anti-CD38 antibodies

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8354411

    1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound

    Expires Mon Jan 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8349886

    Nitrogenated 5-membered heterocyclic compound

    Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8349879

    Tricyclic compound and pharmaceutical use thereof

    Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8344135

    Heterocyclic compound and use thereof

    Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8338461

    1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-)aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8338622

    Heterocyclic compound

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8338462

    1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8337896

    Drug-containing nanoparticles

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8334301

    5-Membered heterocyclic compound

    Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8329900

    Dipeptidyl peptidase inhibitors

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8329691

    Amide compounds and use of the same

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8329687

    Pyridooxazepine derivative and use thereof

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8324201

    Pyrazinooxazepine derivatives

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8324395

    Heterocyclic compound and use thereof

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8324383

    Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8318727

    Polo-like kinase inhibitors

    Expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8318722

    Pyrazinooxazepine derivatives

    Expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8318746

    Nitrogen-containing five-membered heterocyclic compound

    Expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8318939

    Kinase inhibitors

    Expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8314088

    Pyrazinooxazepine derivatives

    Expires Mon Nov 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8309580

    Heterocyclic compound

    Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8304557

    Fused heterocycle derivatives and use thereof

    Expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8299261

    1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors

    Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8293901

    MAPK/ERK kinase inhibitors

    Expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8288539

    Dipeptidyl peptidase inhibitors

    Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8288536

    Kinase inhibitors

    Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8288390

    Benzofuran derivatives

    Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8283353

    Fused ring compound and use thereof

    Expires Mon Oct 04 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8278450

    Kinase inhibitors

    Expires Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8273750

    Organic compounds

    Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8273761

    Tricyclic compound and medical use thereof

    Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Takeda have?

1,436 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Takeda patents expire?

81 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.